A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

NCT01609933 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: ABT-450/r
DRUG: ABT-267
DRUG: pegylated interferon alpha-2a (pegIFN)
DRUG: Ribavirin (RBV)

Sponsor

AbbVie (prior sponsor, Abbott)